Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will participate in two upcoming investor conferences. The first is the Cantor Virtual Global Healthcare Conference scheduled for September 15, 2020, at 10:40 a.m. ET, and the second is the Morgan Stanley Virtual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET. Live webcasts of both events will be available on Halozyme's website, along with an archive for 90 days post-event. Halozyme specializes in biopharmaceutical solutions, notably through its ENHANZE® technology.
Halozyme Therapeutics (NASDAQ: HALO) CEO Dr. Helen Torley will speak at the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 10:00 a.m. ET. Interested participants can access a live webcast through the "Investors" section of Halozyme's website, with an archive available for 90 days post-event. Halozyme specializes in biopharmaceutical solutions, particularly through its ENHANZE® technology that streamlines drug delivery, benefiting over 400,000 patients globally. The company partners with leading firms to enhance treatment efficiency and patient experiences.
Halozyme Therapeutics reported strong Q2 2020 results, achieving its first profitable quarter with earnings per share of $0.19. The company secured multiple FDA and EMA approvals for drugs utilizing its ENHANZE® technology, including Janssen's subcutaneous DARZALEX® and Roche's Phesgo™. Q2 revenue rose to $55.2 million, up from $39.1 million year-over-year, primarily driven by collaboration payments. Halozyme maintains its 2020 revenue guidance of $230 million to $245 million despite potential COVID-19 impacts, emphasizing its commitment to sustainable profitability and capital return through share repurchases.
Halozyme Therapeutics (NASDAQ: HALO) announced Dr. Helen Torley, CEO, will participate in the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 8:30 a.m. ET. A live webcast will be available on Halozyme's website, with an archive accessible for 90 days post-event. Halozyme focuses on optimizing patient experiences and outcomes through its ENHANZE® technology, which facilitates faster drug delivery, benefiting over 400,000 patients globally. The company collaborates with industry leaders to advance innovative therapies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a Quarterly Update Conference Call on August 10, 2020, at 4:30 p.m. ET to discuss its second quarter 2020 financial results, which will be released after market close. Dr. Helen Torley, the CEO, will lead the call. Interested participants can register via a link provided in the announcement. The event will be available for live streaming through the Investors section of Halozyme's website, with a recording accessible afterward. A telephone replay will be available for two weeks post-call.
Summary not available.
Halozyme Therapeutics (NASDAQ: HALO) has announced that Dr. Helen Torley, the president and CEO, will participate in the BMO 2020 Prescriptions for Success Healthcare Conference. The virtual event will be held on June 23, 2020, at 3:00 p.m. ET / 12:00 p.m. PT. A live webcast will be available through the Investors section of Halozyme's website, with an archive accessible for 90 days after the event. Halozyme specializes in innovative solutions for drug delivery, significantly enhancing patient experiences and outcomes through their proprietary ENHANZE® technology.
Halozyme Therapeutics (NASDAQ: HALO) announced positive results from Janssen's Phase III ANDROMEDA study of subcutaneous daratumumab with ENHANZE technology, presented at the European Hematology Association's 25th Annual Congress. The study achieved its primary endpoint, showing hematologic complete response in newly diagnosed light-chain amyloidosis patients. This innovative treatment offers potential benefits for a previously underserved patient population with few options. Halozyme's ENHANZE technology may enhance patient experience by reducing treatment time significantly.